Last reviewed · How we verify
ESBA105
At a glance
| Generic name | ESBA105 |
|---|---|
| Sponsor | ESBATech AG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- ESBA105 in Patients With Severe Dry Eye (PHASE2)
- Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis (PHASE2)
- Ocular Biodistribution Study for Topically Applied ESBA105 (PHASE1, PHASE2)
- Study of ESBA105 Eye Drops in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESBA105 CI brief — competitive landscape report
- ESBA105 updates RSS · CI watch RSS
- ESBATech AG portfolio CI